Li Philip H, Wong Jane C Y, Chan Jacky M C, Chik Thomas S H, Chu M Y, Ho Grace C H, Leung W S, Li Timothy C M, Ng Y Y, Shum Rocky, Sin Winnie W Y, Tso Eugene Y K, Wu Alan K L, Au Elaine Y L
Division of Rheumatology & Clinical Immunology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
Division of Infectious Diseases, Department of Medicine & Geriatrics, Kwong Wah Hospital, Hong Kong SAR, China.
Front Allergy. 2022 Sep 5;3:974138. doi: 10.3389/falgy.2022.974138. eCollection 2022.
Penicillin allergy testing has been traditionally performed by allergists, but there remains a huge deficit of specialists. A multidisciplinary effort with nonallergists would be invaluable to overcome the magnitude of penicillin allergy labels the Hong Kong Drug Allergy Delabelling Initiative (HK-DADI). These consensus statements (CSs) offer recommendations and guidance to enable nonallergists to screen for low-risk (LR) patients and perform penicillin allergy testing.
CSs were formulated by the HK-DADI Group using the Delphi method. An agreement was defined as greater than or equal to 80% consensus.
A total of 26 CSs reached consensus after multiple rounds of Delphi. CSs were categorized into risk assessment, skin testing, drug provocation testing (DPT), and post-testing management. For risk assessment, the essentials of allergy history and exclusion criteria were detailed. Patients with only LR features can proceed with testing by nonallergists. Skin tests should be performed prior to DPT. Details regarding the timing, preparation, and interpretation of skin tests were elaborated. DPT remains the gold standard to diagnose genuine allergy or tolerance and should be performed when there is a low pretest probability following negative skin testing. Details of DPT preparations, dosing protocols, and interpretation were elaborated. For post-testing management, inaccurate allergy labels should be delabeled following negative DPT with proper patient counseling.
CSs support penicillin allergy testing by nonallergists in Hong Kong. LR cases can be managed by nonallergists at Spoke Clinics, with training and support of an allergist-led Hub.
传统上,青霉素过敏测试由过敏症专科医生进行,但专科医生仍然严重短缺。与非过敏症专科医生开展多学科合作对于克服青霉素过敏标签泛滥的问题将非常宝贵,香港药物过敏标签去除倡议(HK-DADI)便是如此。这些共识声明(CSs)提供了建议和指导,以使非过敏症专科医生能够筛查低风险(LR)患者并进行青霉素过敏测试。
HK-DADI小组采用德尔菲法制定了共识声明。达成共识被定义为达成大于或等于80%的一致意见。
经过多轮德尔菲法,共达成了26项共识声明。共识声明分为风险评估、皮肤测试、药物激发试验(DPT)和测试后管理。对于风险评估,详细说明了过敏史的要点和排除标准。只有LR特征的患者可以由非过敏症专科医生进行测试。皮肤测试应在DPT之前进行。详细阐述了皮肤测试的时间、准备和解读。DPT仍然是诊断真正过敏或耐受性的金标准,当皮肤测试为阴性且测试前概率较低时应进行DPT。详细阐述了DPT的准备、给药方案和解读。对于测试后管理,在DPT结果为阴性且对患者进行适当咨询后,应去除不准确的过敏标签。
共识声明支持香港的非过敏症专科医生进行青霉素过敏测试。LR病例可由轮辐诊所的非过敏症专科医生在过敏症专科医生主导的中心的培训和支持下进行管理。